Amneal director exercises options for 20K shares

A director of Amneal Pharmaceuticals exercised vested stock options to acquire additional Class A Common Stock and now holds shares both directly and through a trust.

Available on EDGAR 09/14/2026 - 04:10 PM EDT Accepted by SEC EDGAR 09/14/2026 - 04:10 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. (AMRX) director Kevin J. Buchi exercised options on September 11, 2026 to acquire 20,445 shares of Class A Common Stock at an exercise price of $14.45 per share, eliminating this option position. Following the transaction, he holds 95,522 shares directly and 93,499 shares indirectly through a trust. The exercised option was fully vested and currently exercisable, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

20,445 shares exercised/converted

Exercise 2 txns

Insider BUCHI J KEVIN

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option F1	20,445	$0.00	$0.00
Exercise	Class A Common Stock	20,445	$14.45	$295K
Holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option — 0 contracts (Direct); Class A Common Stock — 95,522 shares (Direct); Class A Common Stock — 93,499 shares (Indirect, By Trust)

Footnotes (1)

1. F1. The option is vested and currently exercisable.

Key Figures

Options exercised: 20,445 shares Exercise price: $14.45 per share Direct holdings after transaction: 95,522 shares +2 more

5 metrics

Options exercised 20,445 shares Stock options exercised by director on September 11, 2026

Exercise price $14.45 per share Exercise price for 20,445 options converted into Class A Common Stock

Direct holdings after transaction 95,522 shares Director’s direct Class A Common Stock position after September 11, 2026 exercise

Indirect holdings by trust 93,499 shares Class A Common Stock held indirectly by trust for the director

Options exercised shares underlying 20,445 shares Underlying Class A Common Stock for the exercised option position

Key Terms

Stock Option, Class A Common Stock, indirect ownership, By Trust

4 terms

Stock Option financial

"A Stock Option was exercised to acquire Class A Common Stock."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Class A Common Stock financial

"The transactions involve shares of Class A Common Stock."

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

indirect ownership financial

"Indirect ownership of shares is reported as held by trust."

By Trust financial

"An indirect holding is described as held By Trust."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Amneal Pharmaceuticals (AMRX) director Kevin J. Buchi do in this Form 4?

He exercised stock options on September 11, 2026 to acquire 20,445 shares of Amneal Pharmaceuticals Class A Common Stock at an exercise price of $14.45 per share, eliminating that particular option position and increasing his direct share ownership.

How many Amneal Pharmaceuticals (AMRX) shares did the director acquire and at what price?

Kevin J. Buchi acquired 20,445 shares of Amneal Pharmaceuticals Class A Common Stock through an option exercise at an exercise price of $14.45 per share on September 11, 2026.

What are Kevin J. Buchi’s direct holdings in AMRX after the reported transactions?

After the reported transactions, Kevin J. Buchi directly holds 95,522 shares of Amneal Pharmaceuticals Class A Common Stock, as of September 11, 2026.

What are the indirect holdings reported for the Amneal Pharmaceuticals (AMRX) director?

In addition to his direct holdings, an indirect position of 93,499 shares of Amneal Pharmaceuticals Class A Common Stock is reported for Kevin J. Buchi, held by trust.

Were the exercised Amneal Pharmaceuticals (AMRX) options already vested?

Yes. A footnote states that the option is vested and currently exercisable, meaning the 20,445 options exercised on September 11, 2026 were fully vested at the time of exercise.

Was the Amneal Pharmaceuticals (AMRX) director’s transaction under a Rule 10b5-1 trading plan?

No. The report indicates no Rule 10b5-1 trading plan for these transactions, so the option exercise on September 11, 2026 is not described as occurring under such a pre-arranged plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BUCHI J KEVIN

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NEW JERSEY 08807

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/11/2026		M		20,445	A	$14.45	95,522	D
Class A Common Stock								93,499	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$14.45	09/11/2026		M			20,445	(1)	11/23/2026	Class A Common Stock	20,445	$0	0	D

Explanation of Responses:

1. The option is vested and currently exercisable.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)